What Is ePRO and Why Clinical Trials in CEE Need It Now

We built Medify because of a gap that shouldn't exist. Electronic Patient Reported Outcomes (ePRO) is a technology that lets patients record symptoms, medication adherence, and quality-of-life data directly through their phones during a clinical trial. It has been a standard in Western Europe and North America for over a decade. In Central and Eastern Europe, most sites still use paper diaries. This isn't a technology problem. It's an access problem. And it's costing the region trials, data quality, and competitive position.

Why ePRO matters now

The global ePRO analytics market reached an estimated $1.83 billion in 2025, growing at a 15.5% compound annual growth rate with projections to $3.25 billion by 2029, driven primarily by the rise of decentralized clinical trials and the demand for real-time patient data.^[1]

Regulators are accelerating this shift. The FDA finalized its guidance on Core Patient-Reported Outcomes in Cancer Clinical Trials in October 2024, followed by PFDD Guidance 3 on fit-for-purpose clinical outcome assessments in October 2025. The EMA has launched parallel initiatives on patient-centric evidence in benefit-risk assessments. These are not recommendations. They are signals that PRO endpoints are becoming central to regulatory strategy.^[2]

What ePRO replaces

In traditional clinical trials, patients record symptoms in paper diaries. The problems with this approach are well documented. Research has shown substantial bias in summary recall, with patients influenced by how they feel at the time of rating rather than their actual experience over the assessment period. Paper diaries also suffer from undocumented compliance. Without timestamps, there is no way to verify when entries were actually made.^[3]

ePRO systems solve both problems. Electronic diaries automatically timestamp all entries, restrict data entry to predefined time windows, allow only valid in-range entries, and can send reminders when entries are due. ePRO applications typically achieve compliance rates of over 80%, often exceeding 90%.^[3]

The gap we set out to close

When we started Medify in 2024, we interviewed 27 clinical trial experts across 43 in-depth conversations. The pattern was consistent: CEE sites want ePRO but can't access it. The platforms that dominate globally are priced for top-20 pharma budgets, take 6 to 12 months to deploy, and treat CEE localization as an afterthought. Meanwhile, sponsors increasingly require electronic data capture across all sites.

The result is a structural disadvantage. CEE sites compete for trials against Western European sites that already offer ePRO-ready infrastructure. Without it, they lose trials to sites that can guarantee electronic data capture, timestamped compliance, and real-time safety monitoring.

We didn't build Medify to add another ePRO vendor to the market. We built it because the existing vendors don't serve this region. No Cyrillic-first interfaces. No offline-first architecture for sites with inconsistent connectivity. No deployment timelines under 6 months. No pricing that works for a 5-site Phase II study in Sofia.

What ePRO delivers in practice

A systematic review and meta-analysis published in the Journal of Medical Internet Research examined randomized controlled trials evaluating ePRO interventions in cancer patients. The analysis found improvement in health-related quality of life at 6 months, particularly in studies that included tailored advice and clinician alerts.^[4]

Beyond clinical outcomes, the operational benefits are substantial. ePRO eliminates transcription errors, enhances timestamp reliability, and supports real-time monitoring by trial teams. Sponsors can instantly flag adverse events or protocol deviations based on direct patient input, rather than retrospective summaries.^[5]

What to look for in an ePRO platform for CEE

Not every ePRO system is suited to the Central and Eastern European clinical research environment. A fit-for-purpose platform should address several key requirements.

Native localization matters. Cyrillic script support, local language interfaces, and culturally adapted patient communication are not optional features. They directly affect patient compliance and data quality.

Offline-first architecture is essential. Many CEE clinical sites operate in areas with inconsistent internet connectivity. An ePRO system that requires constant connectivity will produce data gaps.

Regulatory alignment must be built in, not bolted on. ICH-GCP E6(R3) compliance, EU Annex 11 adherence, GDPR data processing, and EU Clinical Trials Regulation 536/2014 compatibility should be architectural decisions, not configuration options.

The first-mover window

The ePRO adoption gap in CEE is temporary. Every quarter, more global sponsors add electronic data capture to their site selection criteria. The sites that can offer it will attract more trials. The ones that can't will be passed over. This isn't speculation, it's already happening in Phase III oncology trials where sponsor mandates for ePRO compliance have eliminated paper-only sites from consideration.

We've seen this firsthand. In our MVP pilot testing, sites that had never used ePRO before achieved 78% daily active patient usage and 90% data quality scores within the first month. The technology barrier is a myth. The access barrier is real. And it's solvable.

This article is part of our Insights series on clinical trial technology in Central and Eastern Europe.